Neurotune develops medications to treat disorders of the human nervous system and is developing treatments which modulate (tune) the connections between nerve cells and their target cells. As a result of the treatment, the neuromuscular junctions are strengthened. The Company is developing a strong pipeline of drugs targeting large growing markets as well as orphan indications with significant unmet medical need.
The indications include neuromuscular orphan diseases such as ALS, SMA, MG and CMS, nerve injury as well as sarcopenia (age-related loss of muscle mass and strength). The latter affects 20% of people aged 65 and 50% aged 80.
Neurotune employs a strong multi-disciplinary team and maintains an extensive network of international collaborations. It was incorporated in January 2005 and is domiciled in Schlieren-Zurich, Switzerland.